Rep. Jared Moskowitz Purchases Gilead Sciences, Inc. (NASDAQ:GILD) Stock

Representative Jared Moskowitz (Democratic-Florida) recently bought shares of Gilead Sciences, Inc. (NASDAQ:GILD). In a filing disclosed on June 19th, the Representative disclosed that they had bought between $1,001 and $15,000 in Gilead Sciences stock on May 6th. The trade occurred in the Representative’s “MORGAN STANLEY ACTIVE ASSETS (5)” account.

Representative Jared Moskowitz also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Cencora (NYSE:COR) on 5/6/2026.
• Purchased $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 3/31/2026.
• Sold $1,001 – $15,000 in shares of Cummins (NYSE:CMI) on 3/31/2026.
• Purchased $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 3/31/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 3/31/2026.
• Purchased $1,001 – $15,000 in shares of American Express (NYSE:AXP) on 3/31/2026.
• Sold $15,001 – $50,000 in shares of Qualcomm (NASDAQ:QCOM) on 3/31/2026.
• Purchased $1,001 – $15,000 in shares of GE Aerospace (NYSE:GE) on 3/31/2026.
• Purchased $1,001 – $15,000 in shares of McDonald’s (NYSE:MCD) on 3/31/2026.
• Purchased $1,001 – $15,000 in shares of Cencora (NYSE:COR) on 3/31/2026.

Gilead Sciences Price Performance

Gilead Sciences stock remained flat at $131.27 during midday trading on Friday. The company had a trading volume of 7,869,987 shares, compared to its average volume of 8,810,160. The company has a market cap of $162.98 billion, a PE ratio of 17.88 and a beta of 0.32. The business’s 50 day moving average price is $129.44 and its two-hundred day moving average price is $134.53. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 52 week low of $107.75 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the previous year, the company posted $1.81 EPS. The company’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Analysts Set New Price Targets

GILD has been the topic of a number of analyst reports. Citigroup upped their target price on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Weiss Ratings downgraded Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Jefferies Financial Group initiated coverage on Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a research report on Tuesday, June 16th. Finally, The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $158.41.

Institutional Investors Weigh In On Gilead Sciences

Several large investors have recently modified their holdings of the business. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC increased its holdings in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares during the period. Quattro Advisors LLC purchased a new position in Gilead Sciences during the 4th quarter worth approximately $26,000. Wealth Preservation Advisors LLC lifted its stake in Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares during the period. Finally, Wilkerson Advisory Group LLC lifted its stake in Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 78 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the sale, the insider owned 124,234 shares in the company, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the transaction, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This trade represents a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,000 shares of company stock worth $10,824,500 over the last 90 days. 0.30% of the stock is currently owned by company insiders.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida’s 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 23rd Congressional District. He declared candidacy for the 2026 election.

Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor’s degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz’s career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.